SiNtx Technologies, Inc. Common Stock (SINT) is a publicly traded Healthcare sector company. As of May 21, 2026, SINT trades at $2.20 with a market cap of $9.19M and a P/E ratio of -0.43. SINT moved +0.00% today. Year to date, SINT is -40.11%; over the trailing twelve months it is -26.82%. Its 52-week range spans $1.71 to $8.60. Analyst consensus is buy with an average price target of $11.00. Rallies surfaces SINT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
SINTX Technologies Completes First Human Implant and Secures $10M for Commercial Rollout: SINTX Technologies completed the first human surgical procedure using its FDA-cleared SINAPTIC Foot & Ankle Osteotomy Wedge System and appointed Ryan Elmore as President on March 16, 2026. The company raised $10 million in capital, divested non-medical assets, secured a supply deal with Evonik, and initiated AI-assisted 3D manufacturing.
| Metric | Value |
|---|---|
| Price | $2.20 |
| Market Cap | $9.19M |
| P/E Ratio | -0.43 |
| EPS | $-5.06 |
| Dividend Yield | 0.00% |
| 52-Week High | $8.60 |
| 52-Week Low | $1.71 |
| Volume | 3.88K |
| Avg Volume | 0 |
| Revenue (TTM) | $1.03M |
| Net Income | $-10.89M |
| Gross Margin | 46.84% |
2 analysts cover SINT: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $11.00.